-

Seek Labs to Sponsor and Exhibit at the 2024 Next Generation Dx Summit in Washington, D.C.

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and a novel CRISPR-based pharmaceutical technology platform, is excited to announce its sponsorship and participation in the upcoming 2024 Next Generation Dx Summit, hosted by Cambridge Healthtech Institute from August 19-21, 2024, in Washington, D.C. This event brings together global leaders to discuss cutting-edge advancements in diagnostic technologies. Seek Labs’ CEO, Jared Bauer, will be a featured presenter in the Enabling Point-of-Care Diagnostics track on Tuesday, August 20 at 10:00 AM ET. Bauer will discuss the development and optimization of the company’s molecular diagnostic platform, SeekIt™, for point-of-care (POC) applications and reinforce the importance of developing POC diagnostics that meet patient needs. The company will also present two posters at the summit about proprietary nucleic acid extraction and amplification innovations. Attendees can view these posters as part of the Enabling Point-of-Care Diagnostics track from Monday, August 19-Tuesday, August 20.

“We are thrilled to be part of the 2024 Next Generation Dx Summit, an event that aligns perfectly with our mission to revolutionize diagnostics and improve health outcomes for patients globally,” said Jared Bauer, CEO. “This summit provides an invaluable platform for sharing our innovations and engaging with industry leaders who are equally passionate about advancing POC healthcare solutions.”

Seek Labs is a sponsor and exhibitor for the 2024 Next Generation Dx Summit. Attendees can visit the Seek Labs booth (Booth 6) to learn more about the company’s groundbreaking diagnostic innovation, SeekIt, and the key technologies that power accurate and rapid diagnostics outside the lab. The 2024 Next Generation Dx Summit will feature keynote addresses, panel discussions, and an exhibit hall featuring the latest diagnostic technologies.

Seek Labs invites all attendees to join them at the summit to explore the future of diagnostics and discover how SeekIt and other innovations are shaping the industry and transforming patient access to diagnostics.

About Seek Labs

Seek Labs is developing new solutions for point-of-care diagnostics and CRISPR-based pharmaceutical technologies that have the potential to revolutionize the detection and treatment of diseases. Seek Labs is headquartered in Salt Lake City, Utah and is a proud member of the BioHive, a collective representing the life sciences and healthcare innovation ecosystem in Utah.

Contacts

Bridget Baldwin
Director of Communications, Seek Labs
communications@seeklabs.com

Seek Labs


Release Versions

Contacts

Bridget Baldwin
Director of Communications, Seek Labs
communications@seeklabs.com

Social Media Profiles
More News From Seek Labs

Seek Labs Announces Publication in Nature Communications Validating ANINA™, a Room-Temperature, Instrument-Free Amplification Diagnostic Technology Designed to Deliver PCR-Level Sensitivity at the Point of Need

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, announced the publication of a peer-reviewed manuscript in Nature Communications describing Annexing Isothermal Nucleotide Amplification (ANINA™), the proprietary amplification chemistry that powers its SeekIt™ molecular diagnostic platform. The publication, titled “Annexing Isothermal Nucleotide Amplification (ANINA) Enables Probe-Guided Amplification...

Seek Labs Maps 25/25 Viral Families through BioSeeker, Advancing a New Model for Sequence-Directed Antiviral Discovery

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced it has mapped CRISPR-addressable regions across 25 out of 25 viral families known to infect humans, creating a comprehensive atlas of viral genetic vulnerabilities that may support faster identification of antiviral target sites against known pathogens, emerging variants, and future outbreak threats. Antiviral development has been reacti...

Seek Labs Awarded U.S. Patent for Isothermal Molecular Amplification Chemistry Designed for Decentralized Testing

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 12,618,795 B2, covering Asymmetric Semi-Nested Isothermal Nucleotide Amplification (ANINA), a key assay design component of the company’s nucleic acid amplification chemistry for use in molecular diagnostic systems, called Seek Amplification™. Molecular diagnostics...
Back to Newsroom